KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. PMID 38420944 · J Diabetes Sci Technol · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis. PMID 39891102 · BMC Cancer · 2025-Jan-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
NIFTy: near-infrared fluorescence (NIRF) imaging to prevent postsurgical hypoparathyroidism (PoSH) after thyroid surgery-a phase II/III pragmatic, multicentre randomised controlled trial protocol in patients undergoing a total or completion thyroidectomy. PMID 39890139 · BMJ Open · 2025-Jan-30 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. PMID 39887551 · Addiction · 2025-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma. PMID 39885377 · BMC Med Res Methodol · 2025-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial. PMID 39881331 · Trials · 2025-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. PMID 39879593 · N Engl J Med · 2025-Jan-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. PMID 39555826 · N Engl J Med · 2025-Jan-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
CRISPR-Based Therapy for Hereditary Angioedema. PMID 39445704 · N Engl J Med · 2025-Jan-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of SKCPT in patients with knee osteoarthritis: A multicenter, randomized, double-blinded, active-controlled phase III clinical trial. PMID 39303963 · J Ethnopharmacol · 2025-Jan-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
TAD-SIE: sample size estimation for clinical randomized controlled trials using a Trend-Adaptive Design with a Synthetic-Intervention-Based Estimator. PMID 39881374 · Trials · 2025-Jan-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin. PMID 39881222 · BMC Cancer · 2025-Jan-29 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis. PMID 39960455 · Neurology · 2025-Jan-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Remote symptom monitoring with patient-reported outcomes and nudges during lung cancer immunotherapy in China (PRO-NET): protocol for a randomised controlled trial. PMID 39880457 · BMJ Open · 2025-Jan-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane. PMID 39875951 · Cardiooncology · 2025-Jan-28 This is a protocol/design article for an ongoing Phase III randomized trial in oncology with a drug intervention. However, it reports no efficacy results. The primary endpoint (incidence of cardiac dysfunction) is a safety/toxicity endpoint, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required. Therefore, it is excluded as a protocol without results.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy - protocol for the ERADICATE study: a phase II randomised controlled trial. PMID 39875858 · BMC Cancer · 2025-Jan-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. PMID 39875173 · J Immunother Cancer · 2025-Jan-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials. PMID 39715475 · Neurology · 2025-Jan-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial. PMID 39616603 · JAMA · 2025-Jan-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial. PMID 39492713 · Circulation · 2025-Jan-28 The record describes a randomized controlled trial in humans undergoing stem cell transplantation for hematologic malignancies, but it is a non-drug intervention (exercise therapy). The primary endpoints are cardiopulmonary fitness and exercise cardiac function, not time-to-event efficacy (e.g., OS, PFS). Phase is not definitively established as III/IIIb or II/III. Therefore, it does not meet the eligibility criteria for a drug-containing intervention trial with a primary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of subconjunctival TRIamcinolone acetonide injection and intravitreal dexamethasone (OZurdex) injection for uveitic and postoperative macular oedema: the TRIOZ study. PMID 39168590 · Br J Ophthalmol · 2025-Jan-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials. PMID 39871514 · Acta Oncol · 2025-Jan-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
One-stage versus two-stage video-assisted thoracic surgery for synchronous bilateral pulmonary nodules: protocol for a single center, non-randomized clinical trial (OTVATS-1). PMID 39871205 · BMC Surg · 2025-Jan-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study. PMID 39871169 · BMC Cancer · 2025-Jan-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease. PMID 39141589 · Clin Exp Dermatol · 2025-Jan-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer. PMID 39865083 · NPJ Breast Cancer · 2025-Jan-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial. PMID 39675209 · Vaccine · 2025-Jan-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial. PMID 39856583 · BMC Cancer · 2025-Jan-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. PMID 39432738 · Br J Dermatol · 2025-Jan-24 The report describes a randomized trial of a drug (ritlecitinib) for alopecia areata, which is an autoimmune disorder, not a malignant neoplasm. The efficacy endpoints are not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates. PMID 39568595 · RSC Med Chem · 2025-Jan-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Analysis of Research Waste in Phase III/IV Randomized Controlled Trials of Botulinum Toxin Type A. PMID 39840849 · Dermatol Surg · 2025-Jan-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China. PMID 39837901 · Sci Rep · 2025-Jan-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century. PMID 39570146 · Clin Exp Immunol · 2025-Jan-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
[Application Research of Narrative Care to the Management of Symptom Clusters and Post-traumatic Growth in Patients Undergoing Lung Cancer Surgery]. PMID 39988438 · Zhongguo Fei Ai Za Zhi · 2025-Jan-20 The study is a randomized controlled trial in human lung cancer surgery patients, but it evaluates a non-drug nursing intervention (narrative care) for symptom clusters and post-traumatic growth, not a drug-containing intervention. It reports only patient-reported outcome measures (anxiety, sleep, quality of life, post-traumatic growth) at specific time points, without any time-to-event efficacy endpoints. The trial phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors. PMID 39851969 · Curr Oncol · 2025-Jan-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. PMID 39833722 · BMC Cancer · 2025-Jan-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: study protocol for a randomised controlled trial. PMID 39832986 · BMJ Open · 2025-Jan-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A comparative study between central quadrantectomy and nipple resection with areola preservation Versus Grisotti flap mammoplasty in central breast lesions extending to nipple: a randomized clinical trial. PMID 39828867 · J Egypt Natl Canc Inst · 2025-Jan-20 The study is an oncology randomized trial with primary results, but it does not meet the eligibility criteria because it lacks a specified Phase III/II/IIIb designation, involves a non-drug (surgical) intervention only, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. PMID 39432867 · J Clin Oncol · 2025-Jan-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. PMID 39411812 · J Clin Oncol · 2025-Jan-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Artificial Intelligence for Adenoma and Polyp Detection During Screening and Surveillance Colonoscopy: A Randomized-Controlled Trial. PMID 39860586 · J Clin Med · 2025-Jan-17 The study is excluded because it is not a drug intervention trial (it compares an AI-assisted colonoscopy system to standard colonoscopy) and does not report a time-to-event efficacy endpoint required for Kaplan-Meier digitization. While it is an oncology-related RCT in humans, it fails the key criteria of drug intervention and time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. PMID 39846984 · Oncologist · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. PMID 39819527 · CNS Spectr · 2025-Jan-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial. PMID 39693892 · Eur J Cancer · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. PMID 39662097 · Eur J Cancer · 2025-Jan-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. PMID 39576210 · Clin Cancer Res · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial. PMID 39389757 · Gut · 2025-Jan-17 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A Community Health Worker-driven and integrated interactive text messaging intervention to promote smoking cessation and lung cancer screening uptake rates among high-risk Asian immigrants: a feasibility pilot RCT study. PMID 40471875 · Transl Behav Med · 2025-Jan-16 The study is a randomized feasibility pilot of a behavioral and community health intervention for smoking cessation and lung cancer screening uptake. It is not a Phase III/IIIb or Phase II/III drug intervention trial, and it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio. The focus is on feasibility, acceptability, and process outcomes (e.g., screening completion rates), not a definitive efficacy trial for a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Lemborexant on Daytime Functioning in Adults With Insomnia: Patient-Reported Outcomes From a Phase 3 Clinical Trial. PMID 39823487 · Prim Care Companion CNS Disord · 2025-Jan-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Supporting community translation of lung cancer screening: A web-based decision aid to support informed decision making. PMID 39817729 · Transl Behav Med · 2025-Jan-16 The study is a randomized feasibility/acceptability trial of a decision aid for lung cancer screening. While oncology-related and randomized, it is not a Phase III/IIIb or Phase II/III trial with a drug intervention and a primary time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcomes are feasibility metrics, not survival or progression endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -